Evolus delivered Q2 revenue of $84.08M, beating consensus by a meaningful margin, with adjusted EBITDA swinging into positive territory. The 21% year-over-year revenue growth reflects sustained momentum in the U.S. toxin market and international expansion. Adjusted EBITDA profitability—a key metric for device and injectables makers—signals that the company's cost structure is now aligned with its revenue base.
Business & M&A
Evolus Q2 Revenue Surges 21%, Adjusted EBITDA Swings Positive
Jeuveau revenue accelerates past forecasts; adjusted EBITDA turns positive as profitability gains traction.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |